The University of Dublin | Trinity College -- Ollscoil Átha Cliath | Coláiste na Tríonóide
Trinity's Access to Research Archive
Home :: Log In :: Submit :: Alerts ::

TARA >
School of Medicine >
Histopathology & Morbid Anatomy >
Histopathology & Morbid Anatomy (Scholarly Publications) >

Please use this identifier to cite or link to this item: http://hdl.handle.net/2262/63714

Title: A systematic review of platinum and taxane resitance from bench to clinic: An inverse relationship.
Other Titles: Inverse relationship between platinum and taxane resistance
Author: STORDAL, BRITTA KRISTINA
Author's Homepage: http://people.tcd.ie/stordalb
Keywords: Cisplatin
Paclitaxel
Carboplatin
Docetaxel
Ovarian Cancer
Issue Date: 2007
Publisher: WB Saunders
Citation: Stordal, B., Pavlakis, N. and Davey, R., A systematic review of platinum and taxane resitance from bench to clinic: An inverse relationship., Cancer Treatment Reviews, 33, 2007, 688 - 703
Series/Report no.: Cancer Treatment Reviews;33
Abstract: We undertook a systematic review of the pre-clinical and clinical literature for studies investigating the relationship between platinum and taxane resistance. Medline was searched for 1) cell models of acquired drug resistance reporting platinum and taxane sensitivities and 2) clinical trials of platinum or taxane salvage therapy in ovarian cancer. 137 models of acquired drug resistance were identified. 68.1% of cisplatin-resistant cells were sensitive to paclitaxel and 66.7% of paclitaxel-resistant cells were sensitive to cisplatin. A similar inverse pattern was observed for cisplatin vs docetaxel, carboplatin vs paclitaxel and carboplatin vs docetaxel. These associations were independent of cancer type, agents used to develop resistance and reported mechanisms of resistance. 65 eligible clinical trials of paclitaxel-based salvage after platinum therapy were identified. Studies of single agent paclitaxel in platinum-resistant ovarian cancer where patients had previously recieved paclitaxel had a pooled response rate of 35.3% n=232, compared to 22% in paclitaxel naïve patients n=1918 (p<0.01 Chi-squared). Suggesting that pretreatment with paclitaxel may improve the response of salvage paclitaxel therapy. The response rate to paclitaxel/platinum combination regimens in platinum-sensitive ovarian cancer was 79.5% n=88 compared to 49.4% n=85 for paclitaxel combined with other agents (p<0.001 Chi-squared), suggesting a positive interaction between taxanes and platinum. Therefore the inverse relationship between platinum and taxanes resistance seen in cell models is mirrored in the clinical response to these agents in ovarian cancer. An understanding of the cellular and molecular mechanisms responsible would be valuable in predicting response to salvage chemotherapy and may identify new therapeutic targets.
Description: PUBLISHED
URI: http://hdl.handle.net/2262/63714
Appears in Collections:Histopathology & Morbid Anatomy (Scholarly Publications)

Files in This Item:

File Description SizeFormat
2007-StordalCTR-Paclitaxel.pdfPublished (author's copy) - Peer Reviewed377.97 kBAdobe PDFView/Open


This item is protected by original copyright


Please note: There is a known bug in some browsers that causes an error when a user tries to view large pdf file within the browser window. If you receive the message "The file is damaged and could not be repaired", please try one of the solutions linked below based on the browser you are using.

Items in TARA are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback